FGF21 and diabetes mellitus: However, despite as a biomarker and diagnostic indicator of DM-related cardiovascular diseases in clinic (14, 22), the clinical implementation of FGF21 still has some obstacles due to its complex pharmacokinetic and biophysical characteristics (23).